- Home
- HLP vs BYSI Comparison
HLP vs BYSI Comparison
Compare HLP & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- BYSI
- Stock Information
- Founded
- HLP 2021
- BYSI 2010
- Country
- HLP China
- BYSI United States
- Employees
- HLP N/A
- BYSI N/A
- Industry
- HLP Industrial Machinery/Components
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- HLP Industrials
- BYSI Health Care
- Exchange
- HLP Nasdaq
- BYSI Nasdaq
- Market Cap
- HLP 65.3M
- BYSI 71.0M
- IPO Year
- HLP 2023
- BYSI 2017
- Fundamental
- Price
- HLP $0.65
- BYSI $2.05
- Analyst Decision
- HLP
- BYSI
- Analyst Count
- HLP 0
- BYSI 0
- Target Price
- HLP N/A
- BYSI N/A
- AVG Volume (30 Days)
- HLP 79.5K
- BYSI 24.0K
- Earning Date
- HLP 09-18-2025
- BYSI 08-11-2025
- Dividend Yield
- HLP N/A
- BYSI N/A
- EPS Growth
- HLP N/A
- BYSI N/A
- EPS
- HLP N/A
- BYSI N/A
- Revenue
- HLP $14,105,620.00
- BYSI N/A
- Revenue This Year
- HLP N/A
- BYSI N/A
- Revenue Next Year
- HLP N/A
- BYSI N/A
- P/E Ratio
- HLP N/A
- BYSI N/A
- Revenue Growth
- HLP N/A
- BYSI N/A
- 52 Week Low
- HLP $0.61
- BYSI $0.98
- 52 Week High
- HLP $2.13
- BYSI $3.44
- Technical
- Relative Strength Index (RSI)
- HLP 41.42
- BYSI 46.10
- Support Level
- HLP $0.62
- BYSI $1.87
- Resistance Level
- HLP $0.71
- BYSI $2.25
- Average True Range (ATR)
- HLP 0.05
- BYSI 0.16
- MACD
- HLP 0.01
- BYSI 0.01
- Stochastic Oscillator
- HLP 38.14
- BYSI 54.00
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.